VIP and PACAP receptors coupled to adenylyl cyclase in human lung cancer: A study in biopsy specimens

Peptides

Volumn 24, Issue 3, 2003, Pages 429-436

  Busto, Rebeca ^a   Prieto, Juan C ^a   Bodega, Guillermo ^a   Zapatero, José ^b   Fogué, Luis ^c   Carrero, Isabel ^d  

^a UNIVERSITY OF ALCALÁ   (Spain)

^b Clínica Nuestra Señora de la Concepción   (Spain)

^c HOSPITAL RAMÓN Y CAJAL   (Spain)

^d UNIVERSITY OF VALLADOLID   (Spain)

Author keywords

Adenylyl cyclase; Lung cancer; PACAP; Receptors; VIP

Indexed keywords

ADENYLATE CYCLASE; GUANINE NUCLEOTIDE BINDING PROTEIN; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE RECEPTOR; PROTEIN SUBUNIT; RECEPTOR; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR;

ADULT; AGED; ARTICLE; BIOPSY; ENZYME ACTIVITY; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; LUNG BIOPSY; LUNG CANCER; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SAMPLE; STIMULATION;

EID: 0037728734     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0196-9781(03)00058-5     Document Type: Article

References (36)

1. Busto R., Carrero I., Guijarro L.G., Solano R.M., Zapatero J., Noguerales F.et al. Expression, pharmacology and functional evidence for PACAP/VIP receptors in human lung. Am. J. Physiol. 277:1999;L42-L48.
2. Busto R., Prieto J.C., Bodega G., Zapatero J., Carrero I. Immunohistochemical localization and distribution of VIP/PACAP receptors in human lung. Peptides. 21:2000;265-269.
3. Casibang M., Purdom S., Jakowlew S., Neckers L., Zia F., Ben-Av P.et al. Prostaglandin E(2) and VIP increase VEGF mRNAs in lung cancer cells. Lung Cancer. 31:2001;203-212.
4. Csernus V., Schally A.V., Groot K. Effect of GHRH and peptides from the VIP family on cAMP production of human cancer cell lines in vitro. J. Endocrinol. 163:1999;269-280.
5. Davidson A., Moody T.W., Gozes I. Regulation of VIP gene expression in general. Human lung cancer cells in particular. J. Mol. Neurosci. 7:1996;99-110.
6. Dhanasekaran N., Tsim S.T., Dermott J.M., Onesime D. Regulation of cell proliferation by G proteins. Oncogene. 17:1998;1383-1394.
7. Draoui M., Hida T., Jakowlew S., Birrer M., Zia F., Moody T.W. PACAP stimulates c-fos mRNAs in SCLC cells. Life Sci. 59:1996;307-313.
8. Fahrenkrug J., Buhl T., Hannibal J. PreproPACAP-derived peptides occur in VIP-producing tumours and co-exist with VIP. Regul. Pept. 58:1995;89-98.
9. Gelber E., Granoth R., Fridkin M., Dreznik Z., Brenneman D.E., Moody T.W.et al. A lipophilic VIP analog enhances the antiproliferative effect of chemotherapeutic agents on cancer cell lines. Cancer. 92:2001;2172-2180.
10. Gespach C., Bawab W., Cremoux P., Calvo F. Pharmacology, molecular identification and functional characteristics of VIP receptors in human breast cancer cells. Cancer Res. 48:1988;5079-5083.
11. Gonzalez B.J., Basille M., Vaudry D., Fournier A., Vaudry H. Pituitary adenylate cyclase-activating polypeptide. Ann. Endocrinol. (Paris). 59:1998;364-405.
12. Hammond E.H., Yowell R.L., Flinner R.L. Neuroendocrine carcinomas: role of immunocytochemistry and electron microscopy. Hum. Pathol. 29:1998;1367-1371.
13. Harmar A.J., Arimura A., Gozes I., Journot L., Laburthe M., Pisegna J.R.et al. Nomenclature of receptors for VIP and PACAP. Pharmacol. Rev. 50:1998;265-270.
14. Ichikawa S., Nakamura K., Uchino S., Sreedharan S.P. Immunohistochemical localization of the VIP 1 receptor in human uterine adenocarcinoma. Biomed. Res. 17:1996;443-449.
15. Ichikawa S., Sreedharan S.P., Owen R.L., Goetzl E.J. Immunochemical localization of type I VIP receptor and NK-1-type substance P receptor in rat lung. Am. J. Physiol. 268:1995;L584-L588.
16. Korman L.Y., Carney D.N., Citron M.L., Moody T.W. Secretin/VIP stimulated secretion of bombesin-like peptides from human SCLC. Cancer Res. 46:1986;1214-1218.
17. Lee M., Jensen R.T., Huang S.C., Bepler G., Korman L., Moody T.W. VIP binds with high affinity to NSCLC cells and elevates cAMP levels. Peptides. 11:1990;1205-1209.
18. Leyton J., Coelho T., Coy D.H., Jakowlew S., Birrer M.J., Moody T.W. PACAP (6-38) inhibits the growth of prostate cancer cells. Cancer Lett. 125:1998;131-139.
19. Leyton J., Gozes I., Pisegna J., Coy D., Purdom S., Casibang M.et al. PACAP (6-38) is a PACAP receptor antagonist for breast cancer cells. Breast Cancer Res. Treat. 56:1999;177-186.
20. Luis J., Said S.I. Characterization of VIP- and helodermin-preferring receptors on human SCLC cell lines. Peptides. 11:1990;1239-1244.
21. Maruno K., Absood A., Said S.I. VIP inhibits human SCLC proliferation in vitro and in vivo. Proc. Natl. Acad. Sci. USA. 95:1998;14373-14378.
22. Maruno K., Said S.I. VIP inhibits the proliferation of SCLC and NSCLC. Ann. NY Acad. Sci. 805:1996;389-393.
23. Moody T.W., Leyton J., Coelho T., Jakowlew S., Takahashi K., Jameison F.et al. (Stearyl, norleucine17)VIP hybrid antagonizes VIP receptors on NSCLC cells. Life Sci. 61:1997;1657-1666.
24. Moody TW, Zia F, Bitar K, Coy H. PACAP (6-38) is a PACAP type I receptor antagonist on SCLC cells. In: Rosselin G, editor. International Symposium on VIP, PACAP and Related Regulatory Peptides. From molecular biology to clinical applications. Singapore: World Scientific Publishing; 1994. p. 537-44.
25. Moody T.W., Zia F., Draoui M., Brenneman D.E., Fridkin M., Davidson A., Gozes I. A VIP antagonist inhibits NSCLC growth. Proc. Natl. Acad. Sci. USA. 90:1993;4345-4349.
26. Moody T.W., Zia F., Makheja A. PACAP receptors are present on SCLC cells. Peptides. 14:1993;241-246.
27. Ogasawara M., Murata J., Kamitani Y., Hayashi K., Saiki I. Inhibition by VIP of angiogenesis induced by murine Colon 26-L5 carcinoma cells metastasized in liver. Clin. Exp. Metastasis. 17:1999;283-291.
28. Reubi J.C., Läderach U., Waser B., Gebbers J.O., Robberecht P., Laissue J.A. VIP/PACAP receptor subtypes in human tumors and their tissues of origin. Cancer Res. 60:2000;3105-3112.
29. Said SI. Vasoactive intestinal peptide. In: Raebum D, Giembycz MA, editors. Airways smooth muscle: peptide receptors, ion channels and signal transduction. Basel: Birkhäuser Verlag; 1995. p. 87-113.
30. Scholar E.M., Sudhir S.P. Stimulation of tumor cell growth by VIP. Cancer. 67:1991;1561-1564.
31. Shaffer M.M., Carney D.N., Korman L.Y., Lebovic G.S., Moody T.W. High affinity binding of VIP to human lung cancer cell lines. Peptides. 8:1987;1101-1106.
32. Stockhammer G., Obwegeser A., Kostron H., Schumacher P., Muigg A., Felber S.et al. VEGF is elevated in brain tumor cysts and correlates with tumor progression. Acta Neuropathol. (Berl.). 100:2000;101-105.
33. Thakur M.K., Marcus C.S., Saeed S., Pallela V., Minami C., Diggles K.et al. 99mTc-labeled VIP analog for rapid localization of tumors in humans. J. Nucl. Med. 41:2000;107-110.
34. Zia F., Fagarasan M., Bitar K., Coy D.H., Pisegna J.R., Wank S.A.et al. PACAP receptors regulate the growth of NSCLC cells. Cancer Res. 55:1995;4886-4891.
35. Zia H., Hida T., Jakowlew S., Birrer M., Gozes Y., Reubi J.C.et al. Breast cancer growth in inhibited by VIP hybrid, a synthetic VIP receptor antagonist. Cancer Res. 56:1996;3486-3489.
36. Zia H., Leyton J., Casibang M., Hau V., Brenneman D., Fridkin M.et al. (N-stearyl, norleucine17)VIP hybrid inhibits the growth of pancreatic cancer cell lines. Life Sci. 66:2000;379-387.